Hello my frightened friends. Today I will present a company called MAKO Surgical Corp. (MAKO). The stock was now performed spectacularly in a very defficult day for the market. The closing price of MAKO was US$27.39 (+16.50%). The Volume of 2.88M was four times the daily MA. Technically, this stock has a number of positive features. On one side was successful in the test of SMA50. Also, its price exceeded the SM20. All this with very high volume of shares. Our internal indicator, Money Stream, exceeded its SMA22 and MACD showed a significant recovery. In my opinion, MAKO is positioned to record significant progress in the coming weeks and months.
via StockCharts.com
MAKO Surgical Corp., a medical device company, markets its advanced robotic arm solution and orthopedic implants for minimally invasive orthopedic knee procedures primarily in the United States. It offers MAKOplasty, a restorative surgical solution, which enables orthopedic surgeons to treat patient specific early to mid-stage osteoarthritic knee disease. The company also provides robotic arm interactive orthopedic system consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component that offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling minimally invasive, tissue sparing bone removal and knee implant insertion. In addition, it provides tactile guidance system for use with an inlay knee implant system. Further, the company offers the RESTORIS family of knee implant systems comprising unicompartmental knee implant system and multicompartmental knee implant system that are designed for insertion and cementation in a minimally invasive manner. MAKO Surgical Corp. markets its products through direct sales force, as well as through independent orthopedic product agents and distributors. The company was incorporated in 2004 and is headquartered in Fort Lauderdale, Florida. (yahoo finance)
Visit our web page www.themarkettrust.com and take your 30 days free trial in any of our three portfolios. You choose. No Risk.
No comments:
Post a Comment